Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGynecological OncologyVisceral SurgeryDiseaseFallopian Tube CarcinomaOvarian TumorPeritoneal Carcinoma, PrimarySubgroupBRCA mutationserous, borderlineserous, low-gradeICD10C48.-C48.1C56C57.0MeSHCarcinoma, Ovarian EpithelialFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal NeoplasmsSequenceChemotherapyChemo-substanceBevacizumabBinimetinibCisplatinCyclophosphamideNab-paclitaxelNiraparibOlaparibPembrolizumabChemo-substanceBevacizumabBinimetinibCisplatinCyclophosphamideNab-paclitaxelNiraparibOlaparibPembrolizumabChemo-substanceBevacizumabBinimetinibCisplatinCyclophosphamideNab-paclitaxelNiraparibOlaparibPembrolizumabChemo-substanceBevacizumabBinimetinibCisplatinCyclophosphamideNab-paclitaxelNiraparibOlaparibPembrolizumabNo. Substances123 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateNo. Substances235Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRelapse therapySecond lineTherapy phaseMaintenanceTherapy intentionpalliativeRisksAlopeciaAnemia Hb below 8g/dlCardiotoxicityConstipationDiarrheaDyspneaEdemaElectrolyte DisturbanceEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueGastrointestinal ToxicityHeadacheHypertensionHypomagnesemiaIncrease Creatinine PhosphokinaseInfectionsLymphopeniaNeutropeniaPainProteinuriaRashThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorGrisham RNMirza MMoore K / Pujade-Lauraine ETillmanns Tvan Driel WZsiros RDiseaseNeudiagnostiziertes Ovarial-Ca, Eileiter-Ca oder Peritoneal-Ca, Stadium III mit neoadjuvanter Therapie, ECOG 0-2Ovarial-Ca, Rezidiv, platinsensitiv, Zweitlinie, BRCA Mutation, ECOG 0-1Ovarialkarzinom, serös, low-grade oder Borderline-Tumor, Progress nach platinhaltiger Chemotherapierezidivierendes Ovarialkarzinom, fallopian tube or primary peritoneal cancer, ECOG 0-1rezidiviertes Ovarialkarzinom, Eileiterkarzinom oder primäres Peritonealkarzinom, Cisplatin-sensitiv, Drittlinie, ECOG 0-1wiederkehrendes oder fortschreitendes Ovarial-Ca/Peritoneal-Ca, Stadium I-IV, nach Platintherapie, ECOG 0-1OriginDepartment of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New YorkDepartment of Gynecology, Netherlands Cancer Institute, AmsterdamDepartment of Oncology, Rigshospitalet–Copenhagen University Hospital, ENGOT-OV16/NOVA InvestigatorsMemorial Sloan Kettering Cancer Center, Weill Cornell Medical Center, New York, 3 MILO/ENGOT-ov11 StudyStevenson Cancer Center, University of Oklahoma, SOLO2/ENGOT-Ov21 investigatorsThe West Clinic, Memphis, USAProtocols in Revision 6 protocols foundProtocols under revision.Binimetinib 45, Ovarian Ca (PID2671 V1.0)HIPEC - Cisplatin 100, Ovarian ca (PID108 V2.0)Nab-Paclitaxel 100 / Bevacizumab 10, Ovarian ca (PID900 V1.0)Niraparib 300, ovarian carcinoma, maintenance (PID477 V1.1)Olaparib 300, Ovarian ca, maintenance (PID531 V2.0)Pembrolizumab 200 / Bevacizumab 15 / Cyclophosphamide 50, Ovarian ca (PID1109 V1.1)
